Arcturus Therapeutics (ARCT) News Today → [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad) Free ARCT Stock Alerts $38.81 +0.33 (+0.86%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 4:36 AM | marketbeat.comDimensional Fund Advisors LP Raises Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Dimensional Fund Advisors LP grew its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 11.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,May 31 at 4:58 PM | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Down 16.1% in MayArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) saw a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 4,130,000 shares, a decline of 16.1% from the April 30th total of 4,920,000 shares. Currently, 16.8% of the shares of the company are sold short. Based on an average daily trading volume, of 506,100 shares, the days-to-cover ratio is currently 8.2 days.May 28, 2024 | msn.comArcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously OptimisticMay 28, 2024 | marketwatch.comArcturus Therapeutics Shares Jump 23% on Positive Observations for Potential Cystic Fibrosis TreatmentMay 28, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Shares Gap Up to $30.41Arcturus Therapeutics (NASDAQ:ARCT) Shares Gap Up to $30.41May 28, 2024 | businesswire.comArcturus Therapeutics Announces Positive Development for Cystic Fibrosis ProgramMay 27, 2024 | msn.comCSL and Arcturus Announce Breakthrough COVID-19 Vaccine Study ResultsMay 24, 2024 | americanbankingnews.comWilliam Blair Reaffirms Outperform Rating for Arcturus Therapeutics (NASDAQ:ARCT)May 23, 2024 | marketbeat.comWilliam Blair Reiterates Outperform Rating for Arcturus Therapeutics (NASDAQ:ARCT)William Blair restated an "outperform" rating on shares of Arcturus Therapeutics in a report on Thursday.May 22, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Shares Up 5.8%Arcturus Therapeutics (NASDAQ:ARCT) Trading Up 5.8%May 20, 2024 | marketbeat.comAssenagon Asset Management S.A. Acquires Shares of 55,237 Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Assenagon Asset Management S.A. bought a new position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 55,237 shares of theMay 20, 2024 | businesswire.comNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 VaccineMay 20, 2024 | prnewswire.comNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 VaccineMay 19, 2024 | marketbeat.com207,127 Shares in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Acquired by Great Lakes Advisors LLCGreat Lakes Advisors LLC acquired a new stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 207,127 shares of the bioMay 17, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Nikko Asset Management Americas Inc.Nikko Asset Management Americas Inc. lessened its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 4.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,320,652 shares oMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tenaya Therapeutics Amidst Promising Gene Therapy AdvancesMay 16, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Stock Price Up 5.9%Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Up 5.9%May 16, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest UpdateArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 4,920,000 shares, an increase of 6.7% from the April 15th total of 4,610,000 shares. Based on an average daily volume of 506,100 shares, the short-interest ratio is presently 9.7 days. Currently, 20.0% of the shares of the stock are sold short.May 15, 2024 | businesswire.comArcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesMay 12, 2024 | msn.comArcturus Therapeutics (NASDAQ:ARCT) Making Significant Strides Towards GrowthMay 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arcturus Therapeutics Amidst Strong Financial Outlook and Promising Clinical AdvancementsMay 10, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) PT Lowered to $86.00 at Canaccord Genuity GroupCanaccord Genuity Group reduced their price objective on Arcturus Therapeutics from $87.00 to $86.00 and set a "buy" rating for the company in a research note on Friday.May 9, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)May 9, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2024 Earnings Call TranscriptMay 9, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Shares Gap Up to $27.21Arcturus Therapeutics (NASDAQ:ARCT) Shares Gap Up to $27.21May 9, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights:May 9, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights: ...May 9, 2024 | finance.yahoo.comArcturus Therapeutics Holdings First Quarter 2024 Earnings: Beats ExpectationsMay 8, 2024 | investorplace.comARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | sfgate.comArcturus Therapeutics: Q1 Earnings SnapshotMay 8, 2024 | finance.yahoo.comArcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline ProgressMay 2, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Trading Down 6.1%Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 6.1%May 1, 2024 | marketbeat.comArcturus Therapeutics (ARCT) Scheduled to Post Earnings on WednesdayArcturus Therapeutics (NASDAQ:ARCT) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=589903)April 29, 2024 | finance.yahoo.comArcturus Therapeutics Holdings' (NASDAQ:ARCT) investors will be pleased with their impressive 284% return over the last five yearsApril 25, 2024 | businesswire.comArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024April 23, 2024 | seekingalpha.comArcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic FibrosisApril 20, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Sumitomo Mitsui Trust Holdings Inc.Sumitomo Mitsui Trust Holdings Inc. trimmed its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 4.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor oApril 17, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Trading Down 3.2%Arcturus Therapeutics (NASDAQ:ARCT) Trading Down 3.2%April 16, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Trading Up 3.4%Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Up 3.4%April 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and 23andMe Holding (ME)April 14, 2024 | marketbeat.comShort Interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Rises By 14.3%Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 4,810,000 shares, a growth of 14.3% from the March 15th total of 4,210,000 shares. Based on an average trading volume of 454,500 shares, the short-interest ratio is currently 10.6 days. Currently, 19.6% of the shares of the stock are short sold.April 11, 2024 | marketbeat.comVanguard Group Inc. Sells 221,573 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Vanguard Group Inc. trimmed its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 13.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,406,843 shares of the biotechnology compApril 9, 2024 | markets.businessinsider.comAlnylam Pharma Earns Buy Rating on Robust Clinical Trials and Strategic PartnershipsApril 6, 2024 | cnn.comArcturus Therapeutics Holdings, Inc.April 4, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.3% Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.3%April 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arcturus: Promising Vaccine Commercialization and Rare Disease Pipeline ProgressMarch 31, 2024 | marketbeat.comSG Americas Securities LLC Trims Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)SG Americas Securities LLC cut its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 56.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,278 shares of the bMarch 29, 2024 | finanznachrichten.deIntravacc B.V.: Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine DevelopmentMarch 28, 2024 | insidertrades.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Sells $610,573.70 in StockMarch 28, 2024 | marketbeat.comARK Investment Management LLC Acquires 146,141 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)ARK Investment Management LLC boosted its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 7.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,047,687 shares of the biotechnology Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. ARCT Media Mentions By Week ARCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARCT News Sentiment▼0.990.79▲Average Medical News Sentiment ARCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARCT Articles This Week▼93▲ARCT Articles Average Week Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Stoke Therapeutics News PureTech Health News Aurinia Pharmaceuticals News Longboard Pharmaceuticals News Immunome News Tango Therapeutics News Zentalis Pharmaceuticals News Nurix Therapeutics News Disc Medicine News Praxis Precision Medicines News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARCT) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyMAJOR BUY SIGNAL: Move Fast, Washington/Pelosi/Mill…AltimetryUnlock Explosive Gains with This Defense StockBehind the MarketsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin Pro Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
